Nuvisertib Demonstrates Durable Clinical Activity for Patients With R/R Myelofibrosis
According to a phase 1/2 study, nuvisertib (TP-3654), an oral investigational highly selective PIM1 kinase inhibitor, was well-tolerated and demonstrated clinical activity among patients with relapsed/refractory (R/R) myelofibrosis (MF).
These results were presented by Firas El Chaer, MD, University of Virginia Cancer Center, Charlottesville, Virginia at the 66th ASH Annual Meeting in San Diego, California.
“Preliminary data of TP-3654 in relapsed/refractory MF patients showed clinical activity including spleen volume reduction 25, symptom improvement correlating with cytokines reduction, bone marrow fibrosis reduction, and hemoglobin and platelet responses,” wrote El Chaer and colleagues.
“Current monotherapy and preclinical data support the development of TP-3654 in combination with JAK inhibitors ruxolitinib and momelotinib,” they added. Enrollment is ongoing in all 3 arms.
Source:
El Chaer F, Rein L A M, Yuda J, et al. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients. Dec 7-10, 2024; San Diego, CA. Abstract: 655
